Biomea Fusion, Inc.: updates and filings

BMEANASDAQHealthcare · Pharmaceutical Preparations

Price

$0.57

November 20, 2026Market cap $42M

What Ploutos Investor adds for Biomea Fusion

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 75 daysAround Feb 5, 2027 · for Q4 2026

last May 11, 2026next Feb 5, 2027

A rough estimate from when it has reported before, which has varied. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 24, 2026 latest annualNov 10, 2026 latest quarterly
  • Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 10, 2026Financial statements and exhibits
    Form8-K
  • Oct 14, 2026Regulation FD disclosure, other material events
    Form8-K
  • Sep 22, 2026Other material events
    Form8-K
  • Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 5, 2026Financial statements and exhibits
    Form8-K
  • Jun 11, 2026Shareholder vote
    Form8-K
  • May 11, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 11, 2026Results of operations
    Form8-K
  • Apr 28, 2026Regulation FD disclosure, other material events
    Form8-K
  • Apr 27, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 27, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Mar 24, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 24, 2026Results of operations
    Form8-K
  • Feb 25, 2026Regulation FD disclosure
    Form8-K
  • Feb 17, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 12, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Feb 6, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jan 14, 2026Regulation FD disclosure, other material events
    Form8-K
  • Jan 6, 2026Shares registered for employees
    FormS-8
  • Dec 8, 2025Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 14, 2025Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 7, 2025Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 4, 2025Quarterly reportfor the period to Sep 30, 2025
    Form10-Q
  • Nov 4, 2025Results of operations
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 15, 2021.

The full analysis

What do Biomea Fusion's filings show?

The filings are where every one of Biomea Fusion's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.